Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM23RUZ)

Drug Name
JWH-307 Drug Info
Synonyms
914458-26-7; (5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; JWH-307; UNII-06QTR14ONW; 06QTR14ONW; CHEMBL216857; [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone; SCHEMBL17464417; CTK8C0835; DTXSID60581542; ZINC34947163; 5343AC; ANW-65338; BDBM50192607; AKOS016005279; AJ-90459; TC-154083; KB-208480; AX8234389; ST24034774; FT-0747021; (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
16049783
CAS Number
CAS 914458-26-7
TTD Drug ID
DM23RUZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cannabinoid receptor 2 (CB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [2]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [4]
KHK-6188 DMF6CTI Neuropathic pain 8E43.0 Phase 2 [5]
LY-2828360 DMO8IEZ Pain MG30-MG3Z Phase 2 [5]
APD371 DM3XT5V Crohn disease DD70 Phase 2 [6]
S-777469 DMZGNOJ Atopic dermatitis EA80 Phase 2 [7]
842166X DMOV0AP Pain MG30-MG3Z Phase 2 [8]
Beta-caryophyllene DM7583A Pain MG30-MG3Z Phase 2 [9]
Vicasinabin DMF16CU Diabetic retinopathy 9B71.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cannabinoid receptor 1 (CB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [11]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
Orlistat DMRJSP8 Obesity 5B81 Approved [12]
SR141716A DMCO5JZ Obesity 5B81 Approved [13]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [14]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [15]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [4]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [16]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [17]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [1]
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [1]

References

1 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
2 Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
3 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4 Company report (Gwpharm)
5 Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
8 The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
9 The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
10 Clinical pipeline report, company report or official report of Roche
11 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
12 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
13 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
14 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
15 Clinical pipeline report, company report or official report of AstraZeneca (2009).
16 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
17 Clinical pipeline report, company report or official report of Bird Rock Bio.
18 Clinical pipeline report, company report or official report of Affimed Therapeutics.